Expanded Access for AG-221
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Clinical Trials Related to Acute Myeloid Leukemia
Related studies linked through entity extraction aliases.
Haplo HCT vs Haplo-cord HCT for Patients With AML
- Status
- COMPLETED
- Phase
- PHASE3
Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML
- Status
- COMPLETED
- Phase
- N/A
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE2
Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
- Status
- UNKNOWN
- Phase
- N/A
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
- Status
- TERMINATED
- Phase
- PHASE1
A Study of FMT in Patients With AML Allo HSCT in Recipients
- Status
- COMPLETED
- Phase
- PHASE2
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Venetoclax Registry
- Status
- RECRUITING
- Phase
- N/A
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
- Status
- COMPLETED
- Phase
- PHASE1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation
- Status
- UNKNOWN
- Phase
- PHASE3